Patent US5670537A successfully refreshed from Google Patents.
US5670537A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for effecting tumor regression with a low dose, short infusion taxol regimen
Assignee: Bristol Myers Squibb Co
•
Filing: 1996-09-19
•
Granted: 1997-09-23
•
Expires: 2016-09-19
Abstract
Abstract Taxol dosages of about 135 mg/m 2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m 2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H 2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/m 2 and about 175 mg/m 2 of taxol is provided in a 3-hour infusion, following pretreatment to minimize hypersensitivity responses. A method for rechallenging patients with taxol after episodes of acute hypersensitivity reactions is also disclosed, thus enabling patients to continue taxol therapy who would otherwise be deprived of treatment.
Inventors
- 👤 Renzo Mauro Canetta
- 👤 Elizabeth Eisenhauer
- 👤 Marcel Rozencweig
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 13:10
CPC Classifications
A; A61; A61K; A61K45/00; A61K45/06; A61K31/00; A61K31/33; A61K31/335; A61K31/337; A61K31/34; A61K31/395; A61K31/40; A61K31/41; A61K31/415; A61K31/425; A61K31/435; A61K31/44; A61K31/54; A61K31/56; A61K31/57; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/193; A61P; A61P35/00; A61P35/02; A61P37/00; A61P37/08
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
41 words
A method for treating a patient suffering from a taxol-sensitive tumor comprising (i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions, and (ii) parenterally administering to said patient about 135-175 mg/m 2 taxol over about three hours.
Claim 2
Independent Claim
41 words
A method for treating a patient suffering from a taxol-sensitive tumor comprising (i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions, and (ii) parenterally administering to said patient about 135-175 mg/m 2 taxol over about three hours.
Claim 3
Independent Claim
41 words
A method for treating a patient suffering from a taxol-sensitive tumor comprising (i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and (ii) parenterally administering to said patient about 135 mg/m 2 taxol over about three hours.
Claim 4
Independent Claim
41 words
A method for treating a patient suffering from a taxol-sensitive tumor comprising (i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and (ii) parenterally administering to said patient about 135 mg/m 2 taxol over about three hours.
Claim 5
Independent Claim
38 words
A method for treating a patient suffering from a taxol-sensitive ovarian tumor comprising (i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and (ii) parenterally administering to said patient about 135-175 mg/m 2 taxol.
Claim 6
Independent Claim
38 words
A method for treating a patient suffering from a taxol-sensitive ovarian tumor comprising (i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and (ii) parenterally administering to said patient about 135-175 mg/m 2 taxol.
Claim 7
Independent Claim
42 words
A method for treating a patient suffering from a taxol-sensitive ovarian tumor comprising (i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and (ii) parenterally administering to said patient about 135 mg/m 2 taxol over about three hours.
Claim 8
Independent Claim
42 words
A method for treating a patient suffering from a taxol-sensitive ovarian tumor comprising (i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and (ii) parenterally administering to said patient about 135 mg/m 2 taxol over about three hours.
Claim 9
Independent Claim
54 words
A method for treating a cancer patient to effect regression of a taxol-sensitive tumor, said method being associated with reduced hematologic toxicity, said method comprising: (i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and (ii) parenterally administering to said patient about 135-175 mg/m 2 taxol over about 3 hours.
Claim 10
Independent Claim
54 words
A method for treating a cancer patient to effect regression of a taxol-sensitive tumor, said method being associated with reduced hematologic toxicity, said method comprising: (i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and (ii) parenterally administering to said patient about 135-175 mg/m 2 taxol over about 3 hours.
Claim 11
Dependent Claim
33 words
The method of claim 5 wherein the step of premedicating said patient comprises the administration of a medicament selected from the group consisting of steroids, antihistamines, H 2 receptor antagonists, and combinations thereof.
Claim 12
Dependent Claim
13 words
The method of claim 6 wherein said taxol-sensitive tumor is an ovarian tumor.
Claim 13
Independent Claim
54 words
A method for treating a cancer patient to effect regression of a taxol-sensitive tumor, said method being associated with reduced hematologic toxicity, said method comprising: (i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and (ii) parenterally administering to said patient about 135 mg/m 2 taxol over about 3 hours.
Claim 14
Independent Claim
54 words
A method for treating a cancer patient to effect regression of a taxol-sensitive tumor, said method being associated with reduced hematologic toxicity, said method comprising: (i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and (ii) parenterally administering to said patient about 135 mg/m 2 taxol over about 3 hours.
Claim 15
Dependent Claim
33 words
The method of claim 8 wherein the step of premedicating said patient comprises the administration of a medicament selected from the group consisting of steroids, antihistamines, H 2 receptor antagonists, and combinations thereof.
Claim 16
Dependent Claim
13 words
The method of claim 9 wherein said taxol-sensitive tumor is an ovarian tumor.
References Cited (Backward Citations)
WO1993000929A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-09-22 | 2001-03-24 | 2001-09-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-09-22 | 2005-03-24 | 2005-09-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-09-22 | 2009-03-24 | 2009-09-23 | $7700.00 | Window Closed / Lapsed |